2026 · 3rd Quarter (July 1 - Sep 30)

BIOTECHNOLOGY INNOVATION ORGANIZATION (FORMERLY BIOTECHNOLOGY INDUSTRY ORG.)

Filed by CAPITOL COUNSEL LLC.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 20, 2026
Income: $50,000.00
Expenses: Not reported
Registrant: CAPITOL COUNSEL LLC
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (FORMERLY BIOTECHNOLOGY INDUSTRY ORG.)
Filing UUID: 59a80758-0d72-4f78-a626-bc8d29daff55
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

TAX · Taxation/Internal Revenue Code

Legislative and regulatory issues affecting innovation, including vaccines.

TRD · Trade (domestic/foreign)

Issues related to tariffs.

BUD · Budget/Appropriations

Items related to USDA, FDA, genetic engineering, and regulations associated with biotechnology in the Agriculture/Rural Development/Food and Drug Administration proposed Appropriation measures for FY 2027 (House/Senate).

HCR · Health Issues

Public health issues impacting patient access to treatments. Updates and reforms to regulation of treatment development and research.

MMM · Medicare/Medicaid

Medicare Part B coverage and reimbursement issues for biotechnology treatments and issues related to the Medicare Part D coverage, including issues found in H.R. 1, the One Big Beautiful Bill Act (OBBB) P.L. 119-21

Literal federal measure citations: H.R. 1

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.